Cryo-Cell International, Inc.

NYSE American:CCEL

Market Cap

USD 39.68 M

Share Price

USD 4.91

Avg Daily Volume

11,770

Change (1 day)

0.00%

Change (1 year)

-31.62%

Change (YTD)

-33.74%

Cryo-Cell International, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending May 31, 2025: 6.91%

Cryo-Cell International, Inc. EBITDA Margin is 6.91% for the Trailing 12 Months (TTM) ending May 31, 2025, a -122.98% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.
  • Cryo-Cell International, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending May 31, 2024 was -30.06%, a -259.25% change year over year.
  • Cryo-Cell International, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending May 31, 2023 was 18.88%, a 9.41% change year over year.
  • Cryo-Cell International, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending May 31, 2022 was 17.26%, a -32.84% change year over year.
  • Cryo-Cell International, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending May 31, 2021 was 25.69%, a 13.22% change year over year.
Key Data
Date EBITDA Margin Net Income Margin EBT Margin Operating Income Margin